@article {Goto2021.04.29.21256299, author = {Yuka Goto and Yuichiro Nishimoto and Shinnosuke Murakami and Tatsuhiro Nomaguchi and Yuka Mori and Masaki Ito and Ryohei Nakaguro and Toru Kudo and Tsubasa Matsuoka and Takuji Yamada and Toshiki Kobayashi and Shinji Fukuda}, title = {Metabologenomic approach reveals intestinal environmental features associated with barley-induced glucose tolerance improvements in Japanese cohort: a randomized controlled trial}, elocation-id = {2021.04.29.21256299}, year = {2021}, doi = {10.1101/2021.04.29.21256299}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Consumption of barley has been known to exert beneficial effects on metabolic disorders; however, it has also been reported that there are inter-individual differences in these responses. Recent evidence has suggested that these individual differences are mediated by the gut microbiota. Therefore, in the present study, we aimed to understand the relationship between the intestinal environment, including gut microbiota, and metabolic disorders. A randomized controlled trial in Japanese subjects with 4-week consumption of barley or control food was conducted. In this study, we analyzed the intestinal environment, including microbiota and their metabolites, and blood parameters were assessed collectively. We found that microbial genera Blautia and Agathobacter belonging to Lachnospiraceae, and fecal metabolites such as azelate were increased 1.31-fold, 1.84-fold, and 1.48-fold after barley consumption, respectively. Furthermore, the subjects whose glucose tolerance were slightly impaired showed improvement in their glucose tolerance index following the barley consumption. Additionally, the analysis showed that the increase in the abundance of the Anaerostipes was correlated with the improvement in the glucose tolerance index. Our findings indicate that the effects of barley consumption for glucose tolerance are partly defined by the intestinal environment of consumers, providing a quantitative measurement of the dietary effect based on the intestinal environment.Competing Interest StatementThe authors of Y.G, T.M and Toshiki K are employee of Hakubaku Inc., Y.N, T.N, Y.M, M.I, R.N and Toru K are employee of Metabologenomics., Inc. T.Y and S.F are founder of Metabologenomics., Inc. Theres no other no conflict of interests.Clinical TrialUMIN000023675Funding StatementThis research received research support from Hakubaku Inc., and Metabologenomics., IncAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical trial ethics review committee of Chiyoda Paramedical Care ClinicAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll 16S rRNA amplicon sequence files generated in this study are available in DRA of DDBJ (DRA accession number: DRA009319)}, URL = {https://www.medrxiv.org/content/early/2021/04/30/2021.04.29.21256299}, eprint = {https://www.medrxiv.org/content/early/2021/04/30/2021.04.29.21256299.full.pdf}, journal = {medRxiv} }